Previous Article | Next Article ![]()
Journal of Virology, October 1998, p. 8037-8042, Vol. 72, No. 10
DVP/OVRR, Center for Biologics Evaluation and
Research, Food and Drug Administration, Bethesda, Maryland
20892,1 and
Departments of
Psychiatry2 and
Medicine,3 Johns Hopkins University,
Baltimore, Maryland 21205
Received 6 May 1998/Accepted 25 June 1998
Prior to the adoption of widespread vaccination programs, mumps
virus was the leading cause of virus-induced central nervous system
(CNS) disease. Mumps virus-associated CNS complications in vaccinees
continue to be reported; outside the United States, some of these
complications have been attributed to vaccination with insufficiently
attenuated neurovirulent vaccine strains. The development of
potentially neurovirulent, live, attenuated mumps virus vaccines stems
largely from the lack of an animal model that can reliably predict the
neurovirulence of mumps virus vaccine candidates in humans. The lack of
an effective safety test with which to measure mumps virus
neurovirulence has also hindered analysis of the neuropathogenesis of
mumps virus infection and the identification of molecular
determinants of neurovirulence. In this report we show, for the first
time, that mumps virus infection of the neonatal rat leads to
developmental abnormalities in the cerebellum due to
cerebellar granule cell migration defects. The incidence of the
cerebellar abnormalities and other neuropathological and clinical
outcomes of mumps virus infection of the neonatal rat brain
demonstrated the ability of this model to distinguish neurovirulent
(Kilham) from nonneurovirulent (Jeryl Lynn) mumps virus strains. Thus,
this neonatal rat model may prove useful in evaluating the
neurovirulence potential of new live, attenuated vaccine strains and
may also be of value in elucidating the molecular basis of mumps virus
neurovirulence.
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Comparison of the Neurovirulence of a Vaccine and a Wild-Type
Mumps Virus Strain in the Developing Rat Brain
*
Corresponding author. Mailing address:
DVP/OVRR/CBER/FDA, Building 29A, Room 1A-21, 8800 Rockville Pike,
Bethesda, MD 20892. Phone: (301) 827-1973. Fax: (301)
480-5679. E-mail: carbonek{at}a1.cber.fda.gov.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»